Table 3.

Demographic characteristics (sex, race, and age) of patients with each of the 18 studied glomerular disease subtypes

Glomerular disease subtypeMen, % (n)Race, % (n)Mean Age (SD), yr
WhiteBlackLatinoAsianOther
Nephrotic subtypes
 FSGS57.1 (3078/5388)50.6 (2293/4535)45.4 (2060/4535)2.6 (117/4535)0.9 (39/4535)0.6 (26/4535)47.4 (18.0)
 Diabetic glomerulosclerosis54.1 (1632/3019)51.5 (1327/2575)44.6 (1148/2575)2.7 (70/2575)0.7 (18/2575)0.4 (11/2575)56.2 (13.0)
 Membranous nephropathy57.6 (1580/2745)60.2 (1368/2272)36.1 (821/2272)2.2 (49/2272)0.9 (20/2272)0.6 (14/2272)51.2 (16.2)
 Minimal change disease52.4 (595/1136)61.1 (560/916)33.0 (302/916)2.3 (21/916)2.1 (19/916)1.5 (14/916)43.7 (22.4)
 MPGN54.8 (344/628)71.5 (358/501)23.0 (115/501)3.8 (19/501)aa50.8 (19.3)
 Amyloidosis55.0 (264/480)70.3 (286/407)27.3 (111/407)aaa62.9 (11.1)
 MIDD58.7 (135/230)66.3 (134/202)30.7 (62/202)aaa61.8 (12.5)
 Dense deposit disease41.0 (16/39)70.0 (21/30)aaaa33.1 (20.1)
 Fabry disease87.5 (14/16)84.6 (11/13)aaaa40.8 (14.6)
 Collagenofibrotic glomerulopathyaaaaaa35.6 (31.8)
Nephritic subtypes
 Lupus nephritis19.2 (509/2656)28.9 (640/2214)64.3 (1424/2214)4.0 (88/2214)2.1 (46/2214)0.7 (16/2214)35.7 (14.3)
 IgAN63.1 (1383/2191)81.5 (1504/1846)8.5 (157/1846)4.1 (76/1846)3.9 (72/1846)2.0 (37/1846)40.7 (17.4)
 ANCA/pauci-immune GN51.7 (872/1686)81.2 (1151/1417)15.7 (223/1417)1.6 (23/1417)0.9 (12/1417)a60.6 (16.8)
 TBM lesion24.2 (113/467)73.3 (274/374)21.4 (80/374)4.0 (15/374)aa39.9 (16.1)
 Fibrillary GN39.6 (114/288)82.6 (199/241)17.0 (41/241)aaa57.0 (11.2)
 Anti-GBM nephritis51.5 (101/196)85.1 (137/161)11.2 (18/161)aaa53.5 (19.3)
 Alport syndrome57.1 (60/105)76.8 (63/82)15.9 (13/82)aaa25.6 (13.7)
 Immunotactoid GN46.2 (12/26)61.1 (11/18)aaaa49.7 (16.4)
  • Denominator is number of persons with nonmissing data for the variable. MPGN, membranoproliferative GN (nondense deposit disease); MIDD, monoclonal immune deposition disease; IgAN, IgA nephropathy; TBM, thin basement membrane; GBM, glomerular basement membrane.

  • a Cell contains <10 patients.